Expertise in
15
conditions

Dr. Shaji K. Kumar

Hematology | Oncology | Hematology Oncology
200 1st St Sw, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
29 Years of Experience
Expertise in
15
conditions
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shaji Kumar is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Kumar has been practicing medicine for over 29 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Kumar is currently accepting new patients.

His clinical research consists of co-authoring 783 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Additional Areas of Focus

Dr. Kumar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Enrollment Status: Recruiting
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Daratumumab, Dexamethasone, Ixazomib Citrate, Lenalidomide
Study Phase: Phase 2
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Biological, Drug, Other, Procedure
Study Drugs: Daratumumab, Melphalan
Study Phase: Phase 2
Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients
Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients
Enrollment Status: Terminated
Publish Date: May 18, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 1
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dexamethasone, Ixazomib Citrate
Study Phase: Phase 2
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Biological, Drug
Study Drugs: WVT078, WHG626
Study Phase: Phase 1
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2025
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Dexamethasone, Ixazomib Citrate
Study Phase: Phase 1/Phase 2
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination with Ixazomib and Dexamethasone for Patients with Relapsed Multiple Myeloma
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination with Ixazomib and Dexamethasone for Patients with Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Other
Study Drugs: Dexamethasone, Ixazomib Citrate, Venetoclax
Study Phase: Phase 1
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Study Phase: Phase 1/Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2024
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drugs: Dexamethasone, Idasanutlin, Ixazomib Citrate
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Drug
Study Drug: TAK-169
Study Phase: Phase 1
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drugs: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
Study Phase: Phase 2
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Drug, Other
Study Drugs: Dexamethasone, Ixazomib Citrate, Pomalidomide
Study Phase: Phase 2
Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: June 15, 2022
Intervention Type: Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Pomalidomide
Study Phase: Phase 2
Phase 2 Trial of Pembrolizumab, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation
Phase 2 Trial of Pembrolizumab, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia
Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia
Enrollment Status: Withdrawn
Publish Date: December 19, 2018
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 17 Less Clinical Trials

783 Total Publications

Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival.
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: June 13, 2025
Similar Doctors
Expertise in
49
conditions
Dr. Ronald S. Go
Hematology | Oncology | Hematology Oncology
Expertise in
49
conditions
Dr. Ronald S. Go
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 mi)
507-284-2511
Languages Spoken:
English, Filipino, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Go is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Go is highly rated in 49 conditions, according to our data. His top areas of expertise are Rosai-Dorfman Disease, Erdheim-Chester Disease, Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Go is currently accepting new patients.

Expertise in
20
conditions
Dr. David M. Dingli
Hematology | Oncology | Hematology Oncology
Expertise in
20
conditions
Dr. David M. Dingli
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 mi)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Dingli is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Dingli is highly rated in 20 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant. Dr. Dingli is currently accepting new patients.

Expertise in
39
conditions
Dr. Naseema Gangat
Hematology | Oncology | Hematology Oncology
Expertise in
39
conditions
Dr. Naseema Gangat
Hematology | Oncology | Hematology Oncology

Mayo Clinic

Rochester, MN 
 (0.8 mi)
507-255-5123
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Naseema Gangat is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Gangat is highly rated in 39 conditions, according to our data. Her top areas of expertise are Leukocytosis, Essential Thrombocythemia, Myelofibrosis, Bone Marrow Aspiration, and Splenectomy. Dr. Gangat is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile